Researchers are breaking down old barriers by enrolling patients with HIV-associated lymphoma in CAR T and bispecific antibody trials. This shift is forcing a rethink of who gets access to advanced cancer immunotherapies.
Ralph V. Boccia, MD, FACP, pushes for a patient-driven order of CAR T-cell therapy and bispecific antibodies in relapsed myeloma and AL amyloidosis, with MRD negativity now steering key decisions.
Initial Phase 1 results for azer-cel in progressive multiple sclerosis will break cover at MSToronto2026, alongside new BRIUMVI findings. TG Therapeutics aims to push its B-cell therapy ambitions into the spotlight.
OpenCGChromatin, a new open-source tool, lets scientists simulate chromatin folding and molecular interactions at scales that were previously out of reach. The software promises new ways to study DNA packaging and genome structure.
GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.
